AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$SEPN

Septerna, Inc.

Price · $SEPNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $SEPN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $SEPN in the last 30 days.

Top stories · $SEPNMore →
MAY 11·Stock TitanHigh

Septerna moves chronic hives pill toward Phase 2 after Phase 1 study

Septerna (Nasdaq: SEPN) announced its first-quarter 2026 financial results, reporting a narrowed net loss of $8.6 million and $26.5 million in collaboration revenue. The company highlighted positive Phase 1 clinical data for SEP-631, supporting its advancement into Phase 2b for chronic spontaneous urticaria, and the initiation of a Phase 1 trial for SEP-479 for hypoparathyroidism. Septerna projects its $522.1 million cash reserves will fund operations until at least 2029, even as R&D and G&A expenses increased to support pipeline progress.

MAY 1·Stock Titan

Septerna (NASDAQ: SEPN) details 2026 vote on directors and auditor

Septerna, Inc. (NASDAQ: SEPN) has issued a definitive proxy statement (DEF 14A) detailing the agenda for its upcoming 2026 Annual Meeting of Stockholders. The virtual-only meeting will be held on June 26, 2026, at 2:00 p.m. Pacific Time, where shareholders will vote on the election of two Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board of directors recommends voting "FOR" both proposals.

MAR 12·The Globe and Mail

Analysts Conflicted on These Technology Names: Fortinet (FTNT), Septerna, Inc. (SEPN) and Oracle (ORCL)

Analysts have provided conflicting ratings for several technology stocks. Fortinet (FTNT) received a Hold rating from UBS, with a price target of $90.00, alongside a general consensus of Hold. Septerna, Inc. (SEPN) was reiterated as a Buy by H.C. Wainwright with a $40.00 price target and has a Strong Buy consensus. Oracle (ORCL) maintained a Buy rating from TD Cowen with a $250.00 price target, and generally holds a Strong Buy consensus among analysts.

News on $SEPN

All news →